Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Interim analysis (IA) efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of newly diagnosed (1L) patients (pts)
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Moshe Levy, David Andorsky, CelesteAnn Bremer, Joshua Zeidner, Neil Palmisiano, Steven McCune, Anthony Hunter, Zohra Nooruddin, Haifaa Abdulhaq, Vivian Oehler, Shaker Dakhil, Brian Mulherin, Gustavo Fonseca, Michael Heinrich, Omer Jamy, Paul Koller, Koji Sasaki, Islam Mohamad Sadek, Daisy Yang, Dramane Laine, John (randy) Sabo, Amanda Hall, Dheeraj Gianchandani, Michael Mauro, Jorge Cortes, Ehab Atallah
Institutions: Baylor Scott & White Health, Rocky Mountain Cancer Centers, Virginia Oncology Associates, University of North Carolina at Chapel Hill, Rutgers Cancer Institute, WellStar Health System, Emory University, Winship Cancer Institute, The University of Texas at San Antonio Health Science Center, University of California, San Francisco, Fred Hutch Cancer Center, Cancer Center of Kansas, Florida Cancer Specialists & Research Institute, Oregon Health & Science University, University of Alabama at Birmingham, City Of Hope National Medical Center, The University of Texas MD Anderson Cancer Center, Novartis (India), Memorial Sloan Kettering Cancer Center, Medical College of Wisconsin
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417021512
Cites:
Cited by:
Related to: